Methodist Hospitals Becomes First in NWI Region to Offer Patients a New Heart Failure Monitoring Solution - February 18, 2015

Gary & Merrillville, IN— February 2015 — Methodist Hospitals is the first facility in the Northwest Indiana Region to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure.

The CardioMEMS HF System features a sensor that is implanted in the pulmonary artery (PA) during a non-surgical procedure to directly measure PA pressure. Increased PA pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their health care providers allowing for personalized and proactive management to reduce the likelihood of hospitalization.

“The CardioMEMS HF System is a remarkable new technology that enables physicians to improve outcomes for heart failure patients,” said Dr. Kais Yehyawi, Cardiologist at Methodist Hospitals. “In the past, heart failure management has relied on patients reporting symptoms after heart failure have worsened. Cardio MEMS allows physicians to be proactive by adjusting treatment.”

Heart failure occurs when the heart is unable to pump enough blood to meet the body’s demands. According to the Centers for Disease Control and Prevention, more than 5.1 million Americans have heart failure, with 670,000 new cases diagnosed each year. Patients with heart failure are frequently hospitalized, have a reduced quality of life and face a higher risk of death.

On February 4, 2015, six patients at both campuses of Methodist Hospitals were implanted with the CardioMEMS HF sensor. Since this date numerous patients have been implanted with the new sensor.

The CardioMEMS sensor is designed to last the lifetime of the patient and doesn’t require batteries. Once implanted, the wireless sensor sends pressure readings to an external patient electronic system. There is no pain or sensation for the patient during the readings. The CardioMEMS HF System allows the patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.

Data from a clinical trial showed that the CardioMEMS technology reduces heart failure hospital admissions by up to 37 percent. The CHAMPION trial studied the effectiveness of the CardioMEMS HF System in New York Heart Association (NYHA) Functional Classification System class III heart failure patients who had been hospitalized for heart failure in the previous 12 months. Results of the trial demonstrated a statistically significant 28 percent reduction in the rate of heart failure hospitalizations at six months, and 37 percent reduction in heart failure hospitalizations during an average follow-up duration of 15 months.

Roughly 1.4 million patients in the U.S. have NYHA Class III heart failure, and historically these patients account for nearly half of all heart failure hospitalizations. According to the American Heart Association, the estimated direct and indirect cost of heart failure in the U.S. for 2012 was $31 billion and that number is expected to more than double by 2030.

“Methodist Hospitals is committed to improving patient care and investing in innovative medical technology such as the CardioMEMS HF System,” said Dr. Andre Artis, Cardiologist and Medical Director of the Heart and Vascular Institute at Methodist Hospitals. “We are continuously looking to find solutions for successful patient outcomes in the diagnosis and treatment of heart failure.”

The CardioMEMS HF System, from global medical device manufacturer St. Jude Medical, is approved by the U.S. Food and Drug Administration (FDA) for commercial use in the U.S. For more information, visit http://www.heartfailureanswers.com/.

About St. Jude Medical
St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

About Methodist Hospitals

Methodist Hospitals is a community-based, not-for-profit health system with two full-service acute care facilities in Gary and Merrillville, Indiana, that has been leading the way to better health for residents of Northwest Indiana for almost 100 years. Methodist Hospitals offers a number of award – winning programs, including its Neuroscience, Oncology, Heart and Vascular Institutes and Breast Care Center. Its range of services also includes Bariatric Surgery services, Emergency & Trauma services, Orthopedics & Spine services, comprehensive Rehabilitation services, Behavioral Health and Home Health Services.